Hims Highlights Safety and Efficacy of Weight Loss Injection Compared to Ozempic and Wegovy

Hims Reports Safety in Compounded Weight Loss Medication

Hims & Hers Health Inc has announced an analysis showing their weight-loss shot is safe and effective based on a study of over 10,000 patients. Patients initially weighing between 200 and 210 pounds lost approximately 9.3 pounds on average within the first month. Nausea and vomiting were among the side effects, but were mostly considered tolerable.

Market Growth and Important Findings

The compounded version of the medication is aimed at residents who find it challenging to access brand-name alternatives like Novo Nordisk’s Ozempic and Eli Lilly’s Wegovy. The projected market for drugs targeting obesity and diabetes may reach $130 billion by 2030, making this segment a critical focus for the pharmaceutical industry.

• The efficacy and safety of compounded medications are increasingly under scrutiny.
• Hims emphasizes the comparative safety of their products.
• Patients face challenges including high medication costs and limited insurance coverage.

Access and Affordability Concerns

Compared to brand-name medications priced upwards of $1,000 monthly, Hims offers their compounded product at $199 monthly. This significant price difference improves access for many. The lower cost has led to higher retention, with only 13% of customers canceling subscriptions in the first month, compared to 30% for brand-name equivalents.